FDA advisory committees are set to revisit contested applications under renewed emphasis on adcomms, with meetings scheduled that will test the agency’s post-leadership-shakeup approach. Replimune’s twice-rejected melanoma therapy RP1 and Capricor are among the products slated for upcoming scrutiny. The Replimune file is especially notable because FDA decisions on RP1 have already triggered controversy tied to prior leadership departures. The adcomm timing matters for investors and clinicians because it can accelerate clarity on whether the company’s revised evidence package can meet accelerated approval standards. More broadly, the meetings signal that disputed benefit-risk calls will continue to draw public, expert panel pressure rather than remaining solely in internal review lanes.